We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosure information
- Making remissions more common in kidney cancer: a brief history
- Medical therapy for kidney cancer: a brief history
- First immunotherapy revolution: cytokines
- History of immunotherapy for kidney cancer (1)
- RCC is a highly vascular tumor
- VHL/HIF/VEGF signaling pathway (1)
- VHL/HIF/VEGF signaling pathway (2)
- Kidney cancer: most applied sequence, 2007
- History of immunotherapy for kidney cancer (2)
- Remission is possible: outpatient edition
- History of immunotherapy for kidney cancer (3)
- Resurgence of interest
- Nivolumab vs everolimus: a 2015 paper
- Kidney cancer: most applied sequence, 2015
- Strengthen anti-kidney cancer immune response (1)
- Increases in CD8 T cells with combination blockade
- Support for the exploration of kidney cancer biology
- IMmotion150 trial design: randomized P2
- Rational application of kidney cancer therapy
- Confirmation of combination benefit
- Fusion of first and second-line therapy
- Strengthen anti-kidney cancer immune response (2)
- Comparing nivolumab + ipilimumab to sunitinib
- mRCC: Nobel worthy front-line combination therapy?
- First-line phase 3 trials in advanced kidney cancer
- Kidney cancer first-line treatment landscape
- Clinical take-home messages
- Trouble with the curves?
- Could VEGF blockade-driven hypoxia limit the immune response?
- VEGFR TKI in RCC
- Strengthen anti-kidney cancer immune response (3)
- Immune cell priming and activation: durable benefit
- Which PD-1-based combination is superior?
- First-line therapy debate is a waste of time
- Making remissions more common in kidney cancer: focus on the patient's goals
- Focus on the patient's goal = remission
- Early endpoints measure EARLY benefit
- Late endpoints measure LATE benefit
- Does a COMBINATION strengthen anti-kidney cancer immune response?
- Measuring DURABLE benefit in all treated patients
- Approaches that will generate more TFS
- Deep responses = durable survival
- Should we push for deep responses?
- Making remissions more common in kidney cancer: novel therapies from translational research
- Intratumor heterogeneity
- Novel therapies from translational research
- Friends with benefits
- Predictive biomarkers in kidney cancer
- Comprehensive interrogation of the TME
- Rational application of immunotherapy in RCC (1)
- Rational application of immunotherapy in RCC (2)
- Strengthen anti-kidney cancer immune response (4)
- TIM-3 and LAG-3 are co-expressed with PD-1 on terminally exhausted T-cells
- PD-1 + LAG-3 blockade
- Validating targets and engineering T cells
- Strengthen anti-kidney cancer immune response (5)
- Targeting HHLA2/KIR3DL3
- Validate the target in RCC & move to the clinic
- Strengthen anti-kidney cancer immune response (6)
- Engineering immune cells against RCC
- TIL therapy for kidney cancer
- Strengthen anti-kidney cancer immune response (7)
- Targeting HIF-2α in VHL/kidney cancer
- Identify genes with a synthetic lethal relationship with VHL inactivation
- Strengthen anti-kidney cancer immune response (8)
- Developing patient-specific cancer vaccines based on neo-antigens
- Moderna and Merck: randomized trial
- Emerging data which impacts standards of care
- Adjuvant therapy using pembrolizumab
- KEYNOTE-564 study design
- Improvement in disease-free survival for patients receiving pembrolizumab (1)
- Improvement in disease-free survival for patients receiving pembrolizumab (2)
- Interim overall survival analysis
- Risk of recurrence
- KEYNOTE-564: safety summary
- RFS post PD-1 blockade melanoma
- Neoadjuvant therapy
- Case: second-line therapy after PD-1 failure
- Multiple choices, but limited data (1)
- Cabozantinib vs everolimus
- Phase 3 TIVO-3: tivozanib in RCC
- PD-1 blockade salvage therapy
- Multiple choices, but limited data (2)
- Randomized PD-1/VEGF blockade salvage trial was negative
- Multiple choices, but limited data (3)
- HIF-2α inhibition with belzutifan in RCC
- Randomized PD-1/VEGF blockade salvage trial
- Multiple choices, but limited data (4)
- Role of the HIF-2α–VEGF axis in RCC
- HIF-2α + VEGF: increase anti-tumor activity?
- HIF-2α + VEGF: summary of adverse events
- Randomized HIF-2α + VEGF blockade pivotal trial
- Final lesson
- Making remissions more common in kidney cancer
- Standard therapy for mRCC: 2030
- Acknowledgements
Topics Covered
- Kidney cancer
- Immunotherapy in Renal-Cell Carcinoma (RCC)
- VHL/HIF/VEGF signaling pathway
- Development of therapies that generate remissions
- Patient focused objectives
- Tumor microenvironment
- Improving outcomes in advanced kidney cancer
- Novel therapies from translational research
- Cabozantinib, everolimus, nivolumab and relatlimab
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
McDermott, D. (2023, October 31). Making cures more common in kidney cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2024, from https://doi.org/10.69645/MYFW5184.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. McDermott is a consultant for BMS, Pfizer, Merck, Eisai Inc, Xilio, Aveo, Genentech, Cullinan and Exelixis.
Other Talks in the Series: Immunotherapy of Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is David
McDermott and I'm
a Medical Oncologist
here in Boston
at Beth Israel Deaconess
Medical Center.
My talk today is
entitled "Making
Cures More Common
in Kidney Cancer".
Over the last 15 years,
few areas in oncology have seen
more progress than the treatment
of advanced kidney cancer,
due in large part to
the effective application
of immunotherapy.
However, over the last year,
you could make a
strong argument that
things haven't gone well for
immunetherapy in kidney cancer.
During my talk, I
hope to convince
you that to get our
field back on track,
advocates for immunotherapy will
need to refocus on
the field's roots,
which were the rational
application of
immunotherapies to patients
most likely to benefit.
We'll also need to
develop therapies that
generate more remissions
and ultimately cures.
0:55
Here are my disclosures.
0:60
I've divided my talk
into three parts.
In the second section, I will
talk about how my colleagues are
developing new tools to
measure an important
goal of our patients,
remission of their
kidney cancer.
In the third section, I'll
talk about how our team at
the Dana Farber
Harvard Cancer Center
is exploiting a growing
understanding of
the kidney cancer
tumor micro environment to
develop therapies that might
make remissions more common.
I first started treating
patients over 25 years ago when
the median survival
for our patients with
metastatic kidney cancer
was less than one year.
Thanks to team efforts of
patient advocacy groups,
partners in industry,
researchers in basic
translational clinical science,
and most importantly, our brave
patients and their families;
median survival is now
close to five years,
with patients presenting
with metastatic disease.
This improvement is due,
in large part, to the durable
benefit seen with immunotherapy.
Let's start with a
brief history of
its application in solid tumors.